UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	d Address of		2. Issuer Name and Ticker or Trading Symbol Synthetic Biologics, Inc. [SYN]								(Checl	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	st) (First) (Middle)				- 3. Date of Earliest Transaction (Month/Day/Year) 12/04/2019								×	Officer (g below)	ive title	Other (spec below)		
C/O SYNTHETIC BIOLOGICS, INC., 9605 MEDICAL CENTER DRIVE, # 270														CEO a CFO	nd			
(Street) ROCKVILLE MD 20850					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi X	vidual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(9	State)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) Date (Month//						Execution) if any	2A. Deemed Execution Date if any (Month/Day/Ye		Code (Instr.					4 and Securities Beneficial Owned Fo		Form:	Direct d Indirect d str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price	 Reported Transaction(s) (Instr. 3 and 4) 				Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)			ble and	7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4		ount 8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Options	\$0.418	12/04/2019		A		450,000 ⁽¹⁾		12/	/04/2019 ⁽¹	L) 1	2/04/2026	Common Stock	450,000	\$0	450,0	000	D	

Explanation of Responses:

1. These options will vest monthly on a pro rata basis over 36 consecutive months.

/s/ Steven A. Shallcross

** Signature of Reporting Person

<u>12/05/2019</u>

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.